Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual

1 year ago 26

Sincity Press Finance View Original

Seen something newsworthy in Vegas? Let us know.